{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:32:14Z","timestamp":1769560334032,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.msard.2023.104563","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T17:43:45Z","timestamp":1676051025000},"page":"104563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us"],"prefix":"10.1016","volume":"71","author":[{"given":"Celso","family":"Rual","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Lepine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Delourme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette Le","family":"Berre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Treiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6308","authenticated-orcid":false,"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104563_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103926","article-title":"Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: a systematic review","volume":"63","author":"Abbadessa","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.104563_bib0005","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2023.104563_bib0013","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis","volume":"268","author":"Boremalm","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104563_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.104563_bib0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.104563_bib0014","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1007\/s00415-022-11197-6","article-title":"Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression","volume":"269","author":"Dorcet","year":"2022","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104563_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2019","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104563_bib0006","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104563_bib0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfeld","year":"2018","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2023.104563_bib0004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2023.104563_bib0003","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"OLYMPUS trial group Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.104563_bib0009","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104563_bib0018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104563_bib0015","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104563_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia:incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J. Autoimmun."},{"issue":"20","key":"10.1016\/j.msard.2023.104563_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.104563_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2023.104563_bib0002","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104563_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101416","article-title":"Role of B cells and antibodies in multiple sclerosis","volume":"36","author":"Wanleenuwat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:42Z","timestamp":1761901422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":19,"alternative-id":["S2211034823000676"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104563","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104563"}}